Progress in Cancer Drug Resistance Research

One of the main causes of failure in the treatment of cancer is the development of drug resistance by the cancer cells.

Author: Robert A. Parsons

Publisher: Nova Publishers

ISBN: 1600218229

Category: Medical

Page: 223

View: 173

Download →

One of the main causes of failure in the treatment of cancer is the development of drug resistance by the cancer cells. The design of cancer chemotherapy has become increasingly sophisticated, yet there is no cancer treatment that is 100 percent effective against disseminated cancer. Resistance to treatment with anticancer drugs results from a variety of factors including individual variations in patients and somatic cell genetic differences in tumours, even those from the same tissue of origin. Frequently resistance is intrinsic to the cancer, but as therapy becomes more and more effective, acquired resistance has also become common.The most common reason for acquisition of resistance to a broad range of anticancer drugs is expression of one or more energy-dependent transporters that detect and eject anti-cancer drugs from cells, but other mechanisms of resistance including insensitivity to drug-induced apoptosis and induction of drug-detoxifying mechanisms probably play an important role in acquired anticancer drug resistance. Studies on mechanisms of cancer drug resistance have yielded important information on how to circumvent this resistance to improve cancer chemotherapy and have implications for pharmacokinetics of many commonly used drugs.

Related Books

Molecular and Clinical Advances in Anticancer Drug Resistance
Language: en
Pages: 308
Authors: Robert F. Ozols
Categories: Medical
Type: BOOK - Published: 2012-12-06 - Publisher: Springer Science & Business Media

The importance of drug resistance in cancer chemotherapy cannot be over stated. The 500,000 patients who die every year from cancer in the United States have, in most cases, been treated with chemotherapy. Many of these patients responded initially to chemotherapy, but death resulted from the development of drug-resistant tumors.
Anticancer Drug Resistance
Language: en
Pages: 294
Authors: Lori J. Goldstein, Robert F. Ozols
Categories: Medical
Type: BOOK - Published: 2012-12-06 - Publisher: Springer Science & Business Media

Over the last 50 years, drug development and clinical trials have resulted in successful complete responses in diseases such as childhood leukemia, testicular cancer and Hodgkin's disease. We are still, however, confronted with over 500,000 cancer-related deaths per year. Clearly, the phenomenon of drug resistance is largely responsible for these
Cancer Drug Resistance Research Perspectives
Language: en
Pages: 223
Authors: Liman S. Torres
Categories: Medical
Type: BOOK - Published: 2007 - Publisher: Nova Publishers

One of the main causes of failure in the treatment of cancer is the development of drug resistance by the cancer cells. The design of cancer chemotherapy has become increasingly sophisticated, yet there is no cancer treatment that is 100% effective against disseminated cancer. Resistance to treatment with anticancer drugs
Progress in Cancer Drug Resistance Research
Language: en
Pages: 223
Authors: Robert A. Parsons
Categories: Medical
Type: BOOK - Published: 2007 - Publisher: Nova Publishers

One of the main causes of failure in the treatment of cancer is the development of drug resistance by the cancer cells. The design of cancer chemotherapy has become increasingly sophisticated, yet there is no cancer treatment that is 100 percent effective against disseminated cancer. Resistance to treatment with anticancer
Antitumor Drug Resistance
Language: en
Pages: 738
Authors: Brian W. Fox, M. Fox
Categories: Medical
Type: BOOK - Published: 2012-12-06 - Publisher: Springer Science & Business Media

The study of tumour resistance to anticancer drugs has been the subject of many publications since the initial discovery of the phenomenon by J. H. Burchenal and colleagues in 1950. Many papers have been published since then reporting development of resistance to most of the well-known anticancer agents in many